Erin K Mccreary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/815865/publications.pdf

Version: 2024-02-01

43 papers

1,123 citations

623188 14 h-index 32 g-index

44 all docs

44 docs citations

times ranked

44

1873 citing authors

#	Article	IF	CITATIONS
1	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases, 2020, 7, ofaa105.	0.4	255
2	Efficacy of Remdesivir in COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1041.	3.8	94
3	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infectious Diseases, 2018, 5, ofy280.	0.4	83
4	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 2020, 71, 667-671.	2.9	71
5	New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrobial Agents and Chemotherapy, 2021, 65, e0217120.	1.4	65
6	Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infectious Diseases, 2021, 8, ofab254.	0.4	59
7	Appropriateness of Antibiotic Prescribing in United States Children's Hospitals: A National Point Prevalence Survey. Clinical Infectious Diseases, 2020, 71, e226-e234.	2.9	53
8	Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. Open Forum Infectious Diseases, 2020, 7, ofz538.	0.4	52
9	Healthcare practitioners' views of social media as an educational resource. PLoS ONE, 2020, 15, e0228372.	1.1	51
10	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. Clinical Infectious Diseases, 2021, 73, 416-426.	2.9	37
11	Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge. JAMA Network Open, 2022, 5, e2220957.	2.8	37
12	Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Network Open, 2022, 5, e226920.	2.8	24
13	Interplay between Rapid Diagnostic Tests and Antimicrobial Stewardship Programs among Patients with Bloodstream and Other Severe Infections. journal of applied laboratory medicine, The, 2019, 3, 601-616.	0.6	23
14	The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antibodieS through) Tj ETQq0 0 0 rg comparative effectiveness platform trial with response-adaptive randomization. Trials, 2021, 22, 363.	gBT /Overlo 0.7	ock 10 Tf 50 2 20
15	Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience. Drugs - Real World Outcomes, 2020, 7, 13-19.	0.7	19
16	Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic. Open Forum Infectious Diseases, 2021, 8, ofab151.	0.4	19
17	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. Infectious Diseases and Therapy, 2020, 9, 525-536.	1.8	16
18	Vancomycin Combined With Clindamycin for the Treatment of Acute Bacterial Skin and Skin-Structure Infections. Clinical Infectious Diseases, 2015, 61, 1148-1154.	2.9	15

#	Article	IF	CITATIONS
19	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Journal of Antimicrobial Chemotherapy, 2020, 75, 3023-3028.	1.3	13
20	Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 1827.	3.8	12
21	Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21Âdays. Contemporary Clinical Trials, 2022, 113, 106652.	0.8	11
22	In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 93, 258-260.	0.8	10
23	Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Diseases, 2020, 7, ofaa549.	0.4	10
24	High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients. Annals of Pharmacotherapy, 2018, 52, 5-10.	0.9	9
25	Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring. Medical Mycology, 2021, 59, 939-942.	0.3	9
26	Top 10 Myths Regarding the Diagnosis and Treatment of Cellulitis. Journal of Emergency Medicine, 2017, 53, 485-492.	0.3	7
27	Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment. Journal of the American College of Emergency Physicians Open, 2021, 2, e12550.	0.4	7
28	A learning health system approach to the <scp>COVID</scp> â€19 pandemic: <scp>Systemâ€wide</scp> changes in clinical practice and <scp>30â€day</scp> mortality among hospitalized patients. Learning Health Systems, 2022, 6, .	1.1	7
29	Letters of reference for <scp>PGY1</scp> pharmacy residency candidates: A survey of residency program directors and opinion statement. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 379-389.	0.5	7
30	<scp>Teleâ€antimicrobial</scp> stewardship programs: A review of the literature and the role of the pharmacist. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1016-1033.	0.5	6
31	Designing antimicrobial stewardship initiatives to enhance scientific dissemination. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 109-115.	0.5	5
32	1298. Population Pharmacokinetics of Ceftazidime-avibactam among Critically-ill Patients with and without Receipt of Continuous Renal Replacement Therapy. Open Forum Infectious Diseases, 2020, 7, S663-S664.	0.4	4
33	Impact of Clinical Decision Support System Implementation at a Community Hospital With an Existing Tele-Antimicrobial Stewardship Program. Open Forum Infectious Diseases, 2022, 9, .	0.4	4
34	2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections. Open Forum Infectious Diseases, 2019, 6, S768-S768.	0.4	2
35	Longâ€Acting Lipoglycopeptides Can Interfere With Vancomycin Therapeutic Drug Monitoring. Journal of Clinical Pharmacology, 2022, 62, 472-478.	1.0	2
36	Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience. Current Treatment Options in Infectious Diseases, 2017, 9, 356-370.	0.8	1

#	Article	IF	CITATIONS
37	89. Efficacy and Tolerability of Voriconazole (VOR) vs. Isavuconazole (ISA) Prophylaxis (px) in Preventing Invasive Fungal Infections (IFI) in Lung Transplant Recipients (LTR). Open Forum Infectious Diseases, 2019, 6, S6-S7.	0.4	1
38	Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. American Journal of Emergency Medicine, 2020, 38, 321-324.	0.7	1
39	Comprehensive Care Improvement for Oncologic Fever and Neutropenia from a Pediatric Emergency Department. Pediatric Quality & Safety, 2021, 6, e390.	0.4	1
40	668: CRITICAL CARE AND ID PHARMACISTS' BELIEFS ABOUT B-LACTAM THERAPY IN CRITICALLY ILL ADULTS. Critical Care Medicine, 2018, 46, 320-320.	0.4	0
41	656. Prioritizing Gram-Negative Bacteremia (GNB) Cases for Rapid Detection by \hat{l}^2 -Lactam Resistance (BLR) and Patient Outcomes. Open Forum Infectious Diseases, 2019, 6, S301-S302.	0.4	0
42	1042. Antibiotic Stewardship Program (ASP) Implementation of Short-course Antimicrobials for Low-Risk Enterobacteriaceae Blood Stream Infection (EBSI) at a Tertiary Care Center. Open Forum Infectious Diseases, 2019, 6, S367-S367.	0.4	0
43	1709. Epidemiology of Invasive Fungal Infection (IFI) after Severe Influenza Requiring Intensive Care Unit (ICU) Admission: 10-Year Experience at a Tertiary Care Center in the United States. Open Forum Infectious Diseases, 2019, 6, S627-S627.	0.4	O